There has been some surprising and unexpected news recently reported by John’s Hopkins Kimmel Cancer Center. Testosterone, which is believed to be a feeder of prostate cancer has been found to also suppress some advanced prostate cancers and also may reverse resistance the to the testosterone-blocking drugs (ADT) used to treat advanced prostate cancer. The [...]
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Yesterdays Wall Street Journal publish a very important piece by Melinda Beck in their Health Journal (http://tinyurl.com/2dtrrll) . Everyone should go to the piece and read it. The piece, The Prostate Cancer Quandary, has received some play in the prostate community, but its real importance to us has not yet been recognized by our community [...]
What are you going to do if you have had radiation therapy as a primary prostate cancer therapy and the cancer has reoccurred? If the disease has remained in the prostate gland some men are able to go back and have surgery, but the condition the gland has been left in post radiation makes it [...]
In June of 2009 a team at UCSF Department of Urology announced a new prostate cancer risk assessment test that they claim can provide men and their doctors a better way of gauging long-term risks and pinpointing high risk cases of prostate cancer. The test, as indicated by the researchers, proved accurate in predicting bone [...]
Using a CTC-chip that measures the level of circulating tumor cells in blood can provide an important insight into the prognosis and potential rates of recurrent disease, according to data from a developing study at Massachusetts General Hospital, which was presented at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010. [...]
As you already know, I am very interested and a strong believer in the future of immunologic therapy. I have written extensively about Provenge and last week I told you about a phase I clinical trial of a Vaccine Therapy for men with progressive stage D0 (non-metastatic) prostate cancer. (http://advancedprostatecancer.net/?p=1419). I want to now let [...]
The September issue of The Journal of Nuclear Medicine published a study that shows that positron emission tomography (PET)/computer tomography (CT) scans using the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed. Men who elect to have a radical prostatectomy [...]
The absence of a stromal protein called caveolin-1 appears to be a marker for advanced prostate cancer and for metastasis, researchers from the Kimmel Cancer Center at Jefferson and Harvard Medical School reported in "Cell Cycle." Caveolin-1 has already been shown to be a good biomarker serving as a prognostic factor for breast cancer. The [...]
The authors of a recent study from the Duke Prostate Center and Division of Urology, Department of Surgery, Duke University Medical Center, Durham, N.C. and the Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan reviewed the current salvage methods for treating recurrent local recurrent prostate cancer after primary radiotherapy (RT). They used a [...]
